早期类风湿关节炎生物制剂与传统联合治疗的两年疼痛结局:瑞典随机对照试验
瑞典SWEFOT随机对照试验比较甲氨蝶呤(MTX)疗效不足的早期类风湿关节炎(RA)患者加用英夫利西单抗(IFX)或柳氮磺吡啶(SSZ)联合羟氯喹(HCQ)的疼痛轨迹。结果显示,MTX+IFX组累积疼痛曲线下面积(AUC)更低(P=0.01),21个月时不可接受疼痛比例更低(32% vs 45%,调整相对风险0.68 [95%CI 0.51,0.90],P=0.008),但难治性疼痛无组间差异。
要点
- 21个月时MTX+IFX组不可接受疼痛比例32%,低于MTX+SSZ+HCQ组的45%(调整RR 0.68,P=0.008)。
- 难治性疼痛(炎症控制下仍疼痛)占所有不可接受疼痛的82%,两组间无差异。
- 尽管积极联合治疗,21个月时近三分之一早期RA患者仍报告不可接受疼痛。
核心结论
- 在MTX疗效不足的早期RA患者中,加用IFX较加用SSZ+HCQ可降低21个月累积疼痛和不可接受疼痛,但难治性疼痛无组间差异。
研究设计与样本
- 瑞典SWEFOT随机对照开放标签试验,2002年10月至2005年12月入组新发RA患者,MTX治疗3个月未达低疾病活动度(DAS28≤3.2)者随机加用IFX(n=128)或SSZ+HCQ(n=130),随访21个月。
主要发现
- 随机化时50%患者(n=258)报告不可接受疼痛,21个月时降至29%(P<0.001)。
- 意向性分析中MTX+IFX组VAS疼痛AUC低于MTX+SSZ+HCQ组(P=0.01)。
- 21个月时MTX+IFX组32%、MTX+SSZ+HCQ组45%存在不可接受疼痛(调整RR 0.68 [95%CI 0.51,0.90],P=0.008)。
- 难治性疼痛占21个月时所有不可接受疼痛的82%,两组间无差异。
关键数值与推荐
- 不可接受疼痛定义为VAS疼痛评分>40 mm(范围0-100)。
- 难治性疼痛定义为VAS疼痛评分>40 mm且C反应蛋白<10 mg/L。
- 低疾病活动度定义为DAS28≤3.2。
临床怎么用
- 对MTX疗效不足的早期RA患者,加用IFX可能较SSZ+HCQ更有效降低长期疼痛负荷。
- 需关注炎症控制后仍存在的难治性疼痛,现有策略对非炎症性疼痛成分效果不足。
局限性
- 原文未报告局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the pain course between methotrexate (MTX)-refractory early rheumatoid arthritis (RA) patients randomized to infliximab (IFX) versus sulfasalazine (SSZ) plus hydroxychloroquine (HCQ). METHODS: The randomized, controlled, open-label Swedish Pharmacotherapy (SWEFOT) trial enrolled new-onset RA patients from October 2002 to December 2005. After 3 months of receiving MTX, patients not reaching low disease activity (Disease Activity Score in 28 joints score ≤3.2) were randomized to adding IFX (n = 128) or SSZ plus HCQ (n = 130) and followed for 21 months. Here, outcomes included area under the curve (AUC) for visual analog scale (VAS) scores for pain, unacceptable pain (VAS pain score >40 mm [range 0-100]), and unacceptable pain despite inflammation control (refractory pain; VAS pain score >40 plus C-reactive protein level <10 mg/liter). Between-group differences were analyzed with multivariate regression models. RESULTS: Overall, 50% of randomized patients (n = 258) in the crude setting reported unacceptable pain at randomization, declining to 29% at 21 months (P < 0.001), when refractory pain constituted 82% of all unacceptable pain. Comparing randomized arms (intent-to-treat analysis), the AUC for VAS pain was lower in the MTX plus IFX group (P = 0.01), and at 21 months, 32% of patients receiving MTX plus IFX and 45% receiving MTX plus SSZ plus HCQ had unacceptable pain (adjusted relative risk 0.68 [95% confidence interval 0.51, 0.90]; P = 0.008). Regarding refractory pain, no between-group differences were observed. CONCLUSION: Despite active combination treatment, almost one-third of new-onset RA patients reported unacceptable pain after 21 months, and refractory pain constituted more than 4/5 of this pain load. Adding IFX versus SSZ plus HCQ to MTX reduced both cumulative pain and unacceptable pain at 21 months, suggesting less long-term pain for the biologic therapy. These results display insufficient effects of current treatment strategies on inflammation-independent pain components, warranting alternative approaches in affected patients.
引用
- Olofsson T, Wallman JK, Jöud A, et al. Pain Over Two Years After Start of Biologic Versus Conventional Combination Treatment in Early Rheumatoid Arthritis: Results From a Swedish Randomized Controlled Trial. Arthritis Care Res (Hoboken). 2021. PMID: 32433827. doi:10.1002/acr.24264
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。